Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, 69120 Heidelberg, Germany.
Int J Mol Sci. 2022 Jun 30;23(13):7318. doi: 10.3390/ijms23137318.
Current protocols for the differentiation of human-induced pluripotent stem cells (hiPSC) into cardiomyocytes only generate a small amount of cardiac pacemaker cells. In previous work, we reported the generation of high amounts of cardiac pacemaker cells by co-culturing hiPSC with mouse visceral endoderm-like (END2) cells. However, potential medical applications of cardiac pacemaker cells generated according to this protocol, comprise an incalculable xenogeneic risk. We thus aimed to establish novel protocols maintaining the differentiation efficiency of the END2 cell-based protocol, yet eliminating the use of END2 cells. Three protocols were based on the activation and inhibition of the Wingless/Integrated (Wnt) signaling pathway, supplemented either with retinoic acid and the Wnt activator CHIR99021 (protocol B) or with the NODAL inhibitor SB431542 (protocol C) or with a combination of all three components (protocol D). An additional fourth protocol (protocol E) was used, which was originally developed by the manufacturer STEMCELL Technologies for the differentiation of hiPSC or hESC into atrial cardiomyocytes. All protocols (B, C, D, E) were compared to the END2 cell-based protocol A, serving as reference, in terms of their ability to differentiate hiPSC into cardiac pacemaker cells. Our analysis revealed that protocol E induced upregulation of 12 out of 15 cardiac pacemaker-specific genes. For comparison, reference protocol A upregulated 11, while protocols B, C and D upregulated 9, 10 and 8 cardiac pacemaker-specific genes, respectively. Cells differentiated according to protocol E displayed intense fluorescence signals of cardiac pacemaker-specific markers and showed excellent rate responsiveness to adrenergic and cholinergic stimulation. In conclusion, we characterized four novel and END2 cell-independent protocols for the differentiation of hiPSC into cardiac pacemaker cells, of which protocol E was the most efficient.
目前将人类诱导多能干细胞(hiPSC)分化为心肌细胞的方案只能产生少量的心脏起搏细胞。在以前的工作中,我们报道了通过将 hiPSC 与小鼠内脏内胚层样(END2)细胞共培养来产生大量心脏起搏细胞。然而,根据该方案产生的心脏起搏细胞的潜在医学应用包含不可估量的异种风险。因此,我们旨在建立新的方案,保持基于 END2 细胞方案的分化效率,同时消除 END2 细胞的使用。三个方案基于 Wingless/Integrated(Wnt)信号通路的激活和抑制,分别补充维甲酸和 Wnt 激活剂 CHIR99021(方案 B)或 NODAL 抑制剂 SB431542(方案 C)或这三种成分的组合(方案 D)。第四个方案(方案 E)也被使用,它最初是由制造商 STEMCELL Technologies 开发的,用于将 hiPSC 或 hESC 分化为心房心肌细胞。所有方案(B、C、D、E)都与基于 END2 细胞的方案 A 进行了比较,作为参考,比较它们将 hiPSC 分化为心脏起搏细胞的能力。我们的分析表明,方案 E 诱导了 15 个心脏起搏特异性基因中的 12 个上调。相比之下,参考方案 A 上调了 11 个,而方案 B、C 和 D 分别上调了 9、10 和 8 个心脏起搏特异性基因。根据方案 E 分化的细胞显示出强烈的心脏起搏特异性标志物荧光信号,并对肾上腺素能和胆碱能刺激表现出优异的反应性。总之,我们描述了四种新的、不依赖 END2 细胞的 hiPSC 分化为心脏起搏细胞的方案,其中方案 E 最为有效。